Radiation Resistance of Breast Cancer Stem Cells: Understanding the Clinical Framework
Radiation Resistance of Breast Cancer Stem Cells: Understanding the Clinical Framework
复制标题
DOI：
10.1007/s10911-009-9114-z
复制
发表时间：
2009-03-01
影响因子：
2.5
通讯作者：
Woodward, Wendy A.
中科院分区：
文献类型：
--
作者：
Debeb, Bisrat G.;Xu, Wei;Woodward, Wendy A.
对数万名接受放射治疗作为乳腺癌治疗组成部分的妇女进行的荟萃分析表明，放射治疗提高了早期和晚期乳腺癌妇女的总体生存率。然而，数据表明，乳腺癌干/祖细胞可以在辐射后富集，并且乳腺癌干/祖细胞克隆原对辐射特别耐受。潜在耐药乳腺癌干细胞/祖细胞群体似乎在雌激素受体阴性乳腺癌中过度表达，实际上，临床上这些癌症比雌激素受体阳性乳腺癌对辐射更具耐药性。新出现的临床前数据表明，靶向癌症干/祖细胞生存途径可能导致耐药疾病患者亚组的有效放射增敏。在此，临床前研究的临床框架的背景下进行审查。
Meta-analyses of tens of thousands of women treated with radiation as a component of their breast cancer treatment have shown that radiation improves overall survival from breast cancer in women with early stage and advanced disease. However, data suggest that breast cancer stem/progenitor cells can be enriched after radiation and that breast cancer stem/progenitor clonogens are particularly resistant to radiation. Potentially resistant breast cancer stem/progenitor populations appear to be over-represented in estrogen receptor negative breast cancer and indeed, clinically these cancers are more resistant to radiation than estrogen receptor positive breast cancers. Emerging pre-clinical data suggest that targeting cancer stem/progenitor survival pathways may lead to effective radiosensitization in subgroups of patients with resistant disease. Herein, preclinical studies are reviewed in the context of the clinical framework.